Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
Conditions
Interventions
Intervention1: Yukon Choice Flex
Yukon Choice Swift
Ultima PC: Sirolimus Eluting Coronary Stent System (CoCr) will be deplyod on index procedure day.
Control Intervention1: NIL: NIL
Sponsors
Translumina Therapeutics LLP
Eligibility
Inclusion criteria
Inclusion criteria: Real world, all comers ? Indian patients meeting all the below mentioned criteria: 1. Age > 18 years 2. Patients who can provide informed consent form in writing to provide data for the study. 3. Patients who allow their data to be collected for the study at predefined follow-up periods. 4. Patients that need a treatment with drug eluting stent. 5. Presence of one or more coronary artery stenosis in a native coronary artery or a saphenous vein graft from 2.0 to 4.0 mm in diameter planned for PCI with Study device-Sirolimus Eluting Coronary Stent System (CoCr) (one or multiple stents). 6. In case of multiple vessel disease all vessels must be treated with Study device-Sirolimus Eluting Coronary Stent System (CoCr) only 7. No limitation on the number of treated lesions, vessels, and lesion length.
Exclusion criteria
Exclusion criteria: Patients meeting below points will be excluded from the study 1. The Patients treated with stent other than Study device-Sirolimus Eluting Coronary Stent System (CoCr) 2. Patients have other planned coronary vascular treatments after index procedure in same sitting. 3. Patient unwilling or unable to comply with the postoperative visits necessary for data collection. 4. Patient is pregnant or nursing an infant or child or planning to become pregnant while in the study. 5. Concurrent medical condition with a life expectancy of less than 3 years 6. Patient is a recipient of heart transplant 7. Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel or ticagrelor or similar drugs, or any other analogue or derivative, cobalt, chromium or contrast media 8. Prior stenting in target or non-target vessel within 90 days of index procedure 9.Patient participating in other study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Device Oriented Composite endpoints will be captured for below parameters post index procedure: Cardiac Death, Target Vessel related Myocardial Infarction (TV-MI) and Clinically driven Target Lesion Revascularization (TLR) Timepoint: Three year Followup | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical endpoints measured for: 1. Patient Oriented Composite Endpoint (PoCE) defined as the composite of all-cause death, any MI, any stroke and any revascularization 2. Definite/Probable Stent thrombosis as per Academic Research Consortium [ARC] definitions 3. Device success (Defined as successful delivery and deployment of the stent(s) at the intended target lesion (including successful delivery and deployment of multiple overlapping stents) and successful withdrawal of the stent delivery system with attainment of a final residual stenosis of less than 50% of the target lesion as observed by angiography or by visual estimation at index procedure). 4. Procedural success (Defined as attainment of device success without the occurrence of ischemia-driven major adverse cardiac event peri-procedural, post-procedural and within discharge) Timepoint: Clinical endpoints measured at 1 month, 6 months, 1 year, 2 years and 3 years post index procedure | — |
Countries
India
Contacts
Public ContactDr Neeraj Kumar
Translumina Therapeutics LLP
Outcome results
None listed